EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Xi Tan iD, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon

Diabetes, Obesity and Metabolism · 2026-04 · 28 (4) · 2661-2671

DOI: 10.1111/dom.70440 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.01.2026. Verfasst von Xi Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., Plainsboro, New Jersey, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide. Materials and methods This was a retrospective cohort study using Optum's de‐identified Clinformatics Data Mart (Optum CDM) from 1 January 2007 through 30 September 2024. New initiators of semaglutide or dulaglutide ≥18 years with both T2D and ASCVD were included. The index date was the first date of a prescription claim for semaglutide or dulaglutide within the index medication identification period (1 January 2018 through 31 March 2024). The primary outcome was 3‐point MACE (stroke, myocardial infarction [MI], cardiovascular [CV]‐related death). Entropy balancing was applied to balance baseline characteristics. Weighted incidence rates per 1000 person‐years and doubly robust Cox proportional hazard ratios were reported.

Results

There were 75 243 enrolees included (semaglutide, 42 007; dulaglutide, 33 236). The mean age was 68.2 and 69.3 years (unweighted) in the semaglutide and dulaglutide cohorts, respectively. After balancing, standardized mean differences were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesImmunoglobulin Fc FragmentsDiabetes Mellitus, Type 2Recombinant Fusion ProteinsHypoglycemic AgentsAtherosclerosisCardiovascular DiseasesHumansSemaglutideFemaleMaleUnited StatesRetrospective StudiesAgedMiddle AgedDrug Administration Schedule

Stichwörter der Autor:innen

cardiovascular diseasecohort studydulaglutidereal‐world evidencesemaglutidetype 2 diabetes

Substanzen

SemaglutideGlucagon-Like PeptidesdulaglutideImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsHypoglycemic Agents

Autor:innen und Institutionen

  • Novo Nordisk Inc., Plainsboro, New Jersey, USA.
  • Genesis Research Group, Hoboken, New Jersey, USA.
  • Department of Neurology, Center for Brain and Mind Health, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Xi Tan

Förderung

  • Novo Nordisk

Zitieren

APA

Tan, X., Liang, Y., Xie, L., Harton, J., Gutierrez, C., Muhammad, C., Swift, C., & de Havenon, A. (2026). Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States. Diabetes, Obesity and Metabolism, 28(4), 2661-2671. https://doi.org/10.1111/dom.70440

Vancouver

Tan X, Liang Y, Xie L, Harton J, Gutierrez C, Muhammad C, et al. Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States. Diabetes, Obesity and Metabolism. 2026;28(4):2661-2671. doi:10.1111/dom.70440

BibTeX
@article{Tan2026,
  author = {Tan, Xi and Liang, Yuanjie and Xie, Lin and Harton, Joanna and Gutierrez, Cynthia and Muhammad, Chalak and Swift, Caroline and de Havenon, Adam},
  title = {Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {4},
  pages = {2661--2671},
  doi = {10.1111/dom.70440}
}
Kostenlos starten →